Delisting riskPopularity #5,097
20/20 Biolabs (AIDX)
Blood testing for cancer screening and inflammation tracking, plus laboratory services for diagnostic developers.
$0.4510
After hours−0.02 (−4.14%)
At close$0.4705(+0.13%)
In millions of USD, except per-share figures
| In millions | Q1 FY23Mar 2023 | Q2 FY23Jun 2023 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | |
| Research & development | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | |
| General & administrative | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Operating income | −2 | −2 | −2 | −1 | −1 | −1 | −1 | −1 |
| 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −2 |
| Net income from continuing operations | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −2 |
| Net income | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −2 |
| EPS, basic | −$0.42 | −$0.36 | −$0.39 | −$0.26 | −$0.17 | −$0.13 | −$0.20 | −$0.26 |
| EPS, diluted | −$0.42 | −$0.36 | −$0.39 | −$0.26 | −$0.17 | −$0.13 | −$0.20 | −$0.26 |
| Weighted average shares, basic | 5 | 5 | 5 | 5 | 5 | 10 | 11 | 11 |
| Weighted average shares, diluted | 5 | 5 | 5 | 5 | 5 | 10 | 11 | 11 |
| EBITDA | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −1 |